BEIJING, May 19, 2017 /PRNewswire/ -- China Biologic
Products, Inc. ("China Biologic" or the "Company") (NASDAQ: CBPO),
a leading fully integrated plasma-based biopharmaceutical company
in China, announced today that the
Securities and Exchange Commission has declared effective a Form
F-4 Registration Statement, which includes a Proxy Statement of
China Biologic and also constitutes a Prospectus of China Biologic
Products Holdings, Inc. (the "proxy statement/prospectus"), in
connection with the proposed redomicile of China Biologic as a
Cayman Islands company. The
redomicile will be effected through a merger (the "Merger") of
China Biologic with China Biologic Products Holdings, Inc., an
exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary
of China Biologic, resulting in the shares of China Biologic being
converted into the right to receive shares of China Biologic
Products Holdings, Inc.
The Company, with almost all of its current business and
operations conducted outside of the
United States, expects the Merger will improve its ability
to grow both internationally and as well as in China which has a strictly regulated
biopharmaceutical industry that may officially or unofficially
favor companies that are incorporated in jurisdictions that are not
politically and economically perceived to be in competition with
China. Additionally, the proposed
redomicile can result in a reduction in operational,
administrative, legal and accounting costs over the long term.
Holders of China Biologic common stock as of May 17, 2017, the record date, will be asked to
approve the proposed Merger at the 2017 annual meeting of
stockholders, to be held on Friday, June 30,
2017 at 10:00 a.m.,
Beijing time. Stockholders of
record as of the close of business on the record date are entitled
to notice of and vote at the annual meeting, which will be held at
the Company's principal office located at 18th Floor, Jialong
International Building, 19 Chaoyang Park Road, Chaoyang District,
Beijing 100125, People's Republic of China.
China Biologic will commence the mailing of the proxy
statement/prospectus to all holders of China Biologic common stock
as of the record date on May 19,
2017.
The proposed Merger is subject to approval by holders of China
Biologic common stock.
About China Biologic Products, Inc.
China Biologic Products, Inc. (NASDAQ: CBPO) is a leading fully
integrated plasma-based biopharmaceutical company in China. The Company's products are used as
critical therapies during medical emergencies and for the
prevention and treatment of life-threatening diseases and
immune-deficiency related diseases. China Biologic is headquartered
in Beijing and manufactures over
20 different dosage forms of plasma products through its majority
owned subsidiary, Shandong Taibang Biological Products Co., Ltd.,
and its wholly owned subsidiary, Guizhou Taibang Biological
Products Co., Ltd. The Company also has an equity investment in
Xi'an Huitian Blood Products Co., Ltd. The Company sells its
products to hospitals, distributors and other healthcare facilities
in China. For additional
information, please see the Company's website
www.chinabiologic.com.
For more information, please contact:
China Biologic Products, Inc.
Mr. Ming Yin
Senior Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com
ICR Inc.
Mr. Bill Zima
Phone: 1-646-405-5191
E-mail: bill.zima@icrinc.com
Forward-Looking Statements
This release includes forward-looking statements, including
statements regarding the terms and completion of the proposed
Merger, the change in the Company's place of incorporation, the
ability to grow internationally and in China, the reduction in operating expenses
resulting therefrom, the proposal to be approved by the Company's
stockholders at the annual meeting and the commencement of the
mailing of the proxy statement/prospectus. These statements are
forward-looking in nature and subject to risks and uncertainties
that may cause actual results to differ materially. These
uncertainties include, but are not limited to, the ability of the
parties to consummate the proposed Merger, the satisfaction of
closing conditions to consummate the Merger, the Company's ability
to realize the anticipated reduction in operating expenses, and
obtaining requisite approvals, including from the Company's
stockholders. All forward-looking statements included in this
release are based upon information available to the Company as of
the date of this release, which may change, and we assume no
obligation to update any such forward-looking statement.
Additional Information and Where to Find It
This communication is being made in respect of a proposed
redomicile transaction. INVESTORS OF CHINA BIOLOGIC ARE URGED TO READ THE PROXY
STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH
THE SEC BEFORE MAKING A DECISION CONCERNING THE PROPOSED MERGER.
These documents will contain important information that investors
should consider. The proxy statement/prospectus will be mailed to
China Biologic stockholders. The proxy statement/ prospectus and
any other documents filed by China Biologic with the SEC may be
obtained free of charge at the SEC's web site at www.sec.gov. In
addition, investors may obtain free copies of the documents filed
with the SEC by China Biologic by contacting China Biologic's
Investor Relations by phone at +86-10-6598 3177 or by email at
ir@chinabiologic.com.
China Biologic and its respective officers and directors may be
deemed to be participants in the solicitation of proxies in
connection with the proposed Merger. Information regarding the
interests of these directors and executive officers in the proposed
Merger, if any, is included in the proxy statement/prospectus. You
can find information about China Biologic's directors and executive
officers in its proxy statements and Annual Reports on Form 10-K,
previously filed with the SEC. Each of these documents is available
free of charge at the SEC's web site at http://www.sec.gov and
from China Biologic Investor Relations.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/china-biologic-announces-effectiveness-of-registration-statement-and-mailing-of-definitive-proxy-statementprospectus-for-2017-annual-meeting-of-stockholders-300460666.html
SOURCE China Biologic Products, Inc.